The Effect of Inhaled Beta-2 Agonists on Heart Rate in Patients With Asthma: Sensor-Based Observational Study
Open Access
- 11 December 2024
- journal article
- research article
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 8, e56848
Abstract
Background: Beta-2 agonists play an important role in the management of asthma. Inhaled long-acting beta-2 agonists (LABAs) and short-acting beta-2 agonists (SABAs) cause bronchodilation by stimulating adrenoceptors. These receptors are also present in cardiac cells and, as a side effect, could also be stimulated by inhaled beta-2 agonists. Objective: This study aims to assess the effect of beta-2 agonists on heart rate (HR). Methods: The data were retrieved from an observational study, the myAirCoach Quantification Campaign. Beta-2 agonist use was registered by self-reported monthly questionnaires and by smart inhalers. HR was monitored continuously with the Fitbit Charge HR tracker (Fitbit Inc). Patients (aged 18 years and older) were recruited if they had uncontrolled asthma and used inhalation medication. Our primary outcome was the difference in HR between LABA and non-LABA users. Secondary outcomes were the difference in HR on days SABAs were used compared to days SABAs were not used and an assessment of the timing of inhaler use during the day. Results: Patients using LABA did not have a clinically relevant higher HR (average 0.8 beats per minute difference) during the day. Around the moment of SABA inhalation itself, the HR does increase steeply, and it takes 138 minutes before it returns to the normal range. Conclusions: This study indicates that LABAs do not have a clinically relevant effect on HR. SABAs are instead associated with a short-term HR increase. Trial Registration: ClinicalTrials.gov NCT02774772; https://clinicaltrials.gov/study/NCT02774772Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- β2 Agonists2016
- Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control QuestionnaireRespiratory Medicine, 2006
- Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthmaPulmonary Pharmacology & Therapeutics, 2005
- Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrestThe American Journal of Medicine, 2002
- Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmaticsRespiratory Medicine, 1999
- The extrapulmonary effects of increasing doses of formoterol in patients with asthmaEuropean Journal of Clinical Pharmacology, 1998
- Speeds of Action of Single Doses of Formoterol and Salbutamol Compared with Placebo in Reversing Methacholine-induced BronchoconstrictionPulmonary Pharmacology, 1996
- Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthmaThe Lancet, 1990
- Fenoterol in asthmaRespiratory Medicine, 1979
- Dose-response effects of albuterol aerosol compared with isoproterenol and placebo aerosolsJournal of Allergy and Clinical Immunology, 1977